Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
Yes, though rarely: Farxiga (dapagliflozin) can trigger ketoacidosis and serious infections even in people without diabetes, since it is also prescribed for heart failure and chronic kidney disease. Reported risks include euglycemic ketoacidosis (with normal or near-normal blood sugar), urinary tract infections that can progress to pyelonephritis or urosepsis, genital yeast infections, and rare cases of Fournier gangrene, a necrotizing infection of the perineum. Certain triggers raise the odds, including fasting, very low-carb or ketogenic diets, alcohol use, dehydration, surgery, and acute illness, and there are several other factors to consider, so see below to understand the warning signs and timing details that matter most. Symptoms like nausea, vomiting, abdominal pain, deep or rapid breathing, unusual fatigue, fever, or genital pain, swelling, or redness warrant urgent evaluation, because these conditions can escalate quickly and are easy to mistake for a stomach bug. If you are noticing anything unusual while taking Farxiga, a free, instant, online symptom check can help you sort out how urgent your situation may be and what to ask your clinician next.
Last reviewed for medical accuracy: 09/17/2026
Farxiga (dapagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for managing type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Increasingly, clinicians are exploring its benefits beyond diabetes, including weight management and cardiovascular protection in non-diabetic patients. While Farxiga can offer meaningful health gains, it carries rare but serious risks—most notably urogenital infections and ketoacidosis—even in people without diabetes. Understanding these potential complications, their warning signs and preventive steps will help you make informed decisions and stay safe.
Farxiga blocks SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. This leads to:
Because it acts independently of insulin, Farxiga can trigger side effects related to extra glucose in the urine and shifts in energy metabolism.
By increasing urinary glucose, Farxiga creates an environment where bacteria and fungi can flourish. Common and rare infections include:
• Genital yeast infections
– More frequent in women (vaginal yeast) and uncircumcised men (balanitis)
– Symptoms: itching, redness, unusual discharge or odor
• Urinary tract infections (UTIs)
– Symptoms: burning on urination, frequent urges, cloudy or bloody urine
• Fournier’s gangrene (necrotizing fasciitis of the genital region)
– Very rare but life-threatening
– Warning signs: severe pain, swelling, redness in the genital/perineal area, fever
Preventive steps:
Ketoacidosis is a state of dangerously high blood acid (ketone) levels. While classic diabetic ketoacidosis (DKA) occurs in type 1 diabetes, SGLT2 inhibitors can cause euglycemic ketoacidosis—even when blood glucose is only mildly elevated or normal. Key points for non-diabetic Farxiga users:
• Why it happens
– Reduced insulin levels and increased glucagon trigger fat breakdown.
– The liver produces ketones for energy, which can accumulate.
• Risk factors
– Low-carb or ketogenic diets
– Prolonged fasting or very low-calorie intake
– Excessive alcohol consumption
– Acute illness, surgery or severe dehydration
– Strenuous exercise without adequate carbohydrate intake
• Symptoms to watch for
– Nausea, vomiting or abdominal pain
– Unusual fatigue or sleepiness
– Rapid breathing or shortness of breath
– Confusion or difficulty concentrating
Even with normal blood sugar readings, these symptoms may signal euglycemic ketoacidosis. This condition can be life-threatening if not treated promptly.
Early detection is crucial. If you’re taking Farxiga without diabetes—or if your blood sugar is normal—stay alert to:
Immediate steps:
For non-diabetics, Farxiga’s off-label uses (e.g., heart failure, kidney protection, weight management) often hinge on shared decision-making between you and your healthcare provider. The likelihood of serious infection or ketoacidosis is low but real. Discuss these questions with your doctor:
• Stay hydrated—aim for 8 to 10 cups of fluid daily unless otherwise directed.
• Maintain balanced nutrition—avoid extreme low-carb diets without medical supervision.
• Practice thorough genital hygiene—wash daily and after exercise.
• Schedule regular follow-ups—monitor kidney function, electrolytes and ketones if advised.
• Keep emergency contacts and your prescribing doctor’s number handy.
You know your body best. If you experience any of the following, don’t wait:
For an immediate, confidential assessment of your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you determine if urgent care is needed and guide your next steps: https://ubiehealth.com/
Information in this article is drawn from authoritative sources, including:
Farxiga offers significant benefits beyond blood sugar control, but it isn’t risk-free. Even non-diabetic users can face serious infections and ketoacidosis. By understanding risk factors, recognizing warning signs and staying vigilant, you can maximize the benefits while minimizing harm.
Always speak to a doctor about anything that could be life-threatening or serious. Your healthcare provider can tailor monitoring and preventive strategies to your individual needs, ensuring you get the most from Farxiga with the greatest possible safety.
(References)
* Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. PMID: 28105986; PMCID: PMC5292646.
* Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
* Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019 Jul;79(10):1135-1146. doi: 10.1007/s40265-019-01148-3. PMID: 31236801; PMCID: PMC6879440.
* Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, Zahoor S. Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin. Cureus. 2022 Jan;14(1):e21720. doi: 10.7759/cureus.21720. Epub 2022 Jan 29. PMID: 35251794; PMCID: PMC8887691.
* Newland DM, Law YM, Albers EL, Friedland-Little JM, Ahmed H, Kemna MS, Hong BJ. Early Clinical Experience with Dapagliflozin in Children with Heart Failure. Pediatr Cardiol. 2023 Jan;44(1):146-152. doi: 10.1007/s00246-022-02983-0. Epub 2022 Aug 10. PMID: 35948644.
* Lava SAG, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review. Paediatr Drugs. 2024 May;26(3):229-243. doi: 10.1007/s40272-024-00623-z. Epub 2024 Apr 18. PMID: 38635113.
* Tavares CAM, Azevedo LCP, Rea-Neto Á, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-João PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimarães-Júnior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J, Neves FMO, Paulo JA, Albuquerque CSN, Silva MCR, Kosiborod MN, Pereira AJ, Damiani LP, Corrêa TD, Serpa-Neto A, Berwanger O, Zampieri FG, DEFENDER Investigators. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial. JAMA. 2024 Aug 6;332(5):401-411. doi: 10.1001/jama.2024.10510. PMID: 38873723; PMCID: PMC11304119.
* Engström A, Söderling J, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Pasternak B, Ueda P. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):432-443. doi: 10.1093/ehjcvp/pvae045. PMID: 38918063; PMCID: PMC11411209.
* Shin H, Paik JM, Everett BM, DiCesare E, Alix C, Glynn RJ, Wexler DJ, Patorno E. Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors. JAMA Intern Med. 2025 Mar 1;185(3):302-313. doi: 10.1001/jamainternmed.2024.7357. PMID: 39836397; PMCID: PMC11877166.
* Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, González Ferreiro R, González Bermúdez I, Lopez Otero D, Nombela-Franco L, Gheorghe L, Diez JL, Baladrón Zorita C, Baz JA, Muñoz García AJ, Vilalta V, Ojeda-Pineda S, de la Torre Hernández JM, Cordoba Soriano JG, Regueiro A, Bordes Siscar P, Salgado Fernández J, Garcia Del Blanco B, Martín-Reyes R, Romaguera R, Moris C, García Blas S, Franco-Peláez JA, Cruz-González I, Arzamendi D, Romero Rodríguez N, Díez-Del Hoyo F, Camacho Freire S, Bosa Ojeda F, Astorga Burgo JC, Molina Navarro E, Caballero Borrego J, Ruiz Quevedo V, Sánchez-Recalde Á, Peral Disdier V, Alegría-Barrero E, Torres-Llergo J, Feltes G, Fernández Díaz JA, Cuellas C, Jiménez Britez G, Sánchez-Rubio Lezcano J, Barreiro-Pardal C, Núñez-Gil I, Abu-Assi E, Iñiguez-Romo A, Fuster V, Ibáñez B, DapaTAVI Investigators. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. PMID: 40162639.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.